Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
about
Fast-track drug approval in inflammatory bowel diseasesFDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements.User fees and beyond--the FDA Safety and Innovation Act of 2012Regulatory review of novel therapeutics--comparison of three regulatory agencies.Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014Developing standards for breakthrough therapy designation in oncology.A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancer.Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?Early market access of cancer drugs in the EU.Use of the conditional marketing authorization pathway for oncology medicines in Europe.How do we avoid disaster when exiting the European Medicines Agency? Making the most of Brexit in pharmaceutical regulation.Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews.Pattern and impact of drugs targeted toward toxicity amelioration in patients receiving cancer chemotherapy.Response to letter to the editor regarding Alqahtani et al. Article on priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
P2860
Q28077510-4793FEEA-861E-46E8-A1EE-3AB49BDD770AQ34359341-12AA7B35-F24F-4EF8-9528-9F3200032A80Q34649639-D8945C2D-257B-4ADC-9F2E-DE4BD8235A55Q36417844-B9B2792E-C2F4-484A-B6C6-1A3ECFD25D1FQ37063626-E98434D8-2451-4A2D-90F0-7B0541A6CBC9Q37100184-8EBEE14A-7AB5-4E01-A0F9-5800F1A95274Q37161896-2F66B242-9205-4B17-82AD-1252280E7CBDQ37313289-7D6C0F6E-04A1-4DF6-B758-E8E5FCBE0924Q38503395-6225F97C-9E1E-4891-A20E-190FD73B8688Q38612833-AD8540E5-7164-403C-8C4A-D8E709804FE1Q40830005-770B64C6-2B97-4F8D-8CEF-235AFF05E54EQ42332992-8D58292F-722F-42C9-970C-CFE1C5E13885Q47620205-61793239-C5BC-4478-B5BD-2C7FE5623C8AQ49674404-0E8DE129-9EC5-4C34-B22A-BF1AD5BEA433Q53047437-05CEDC05-A4E2-493F-8982-FB26A8C44ECF
P2860
Despite criticism of the FDA review process, new cancer drugs reach patients sooner in the United States than in Europe.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 June 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Despite criticism of the FDA r ...... United States than in Europe.
@en
Despite criticism of the FDA r ...... United States than in Europe.
@nl
type
label
Despite criticism of the FDA r ...... United States than in Europe.
@en
Despite criticism of the FDA r ...... United States than in Europe.
@nl
prefLabel
Despite criticism of the FDA r ...... United States than in Europe.
@en
Despite criticism of the FDA r ...... United States than in Europe.
@nl
P2093
P1433
P1476
Despite criticism of the FDA r ...... United States than in Europe.
@en
P2093
Ellen V Sigal
Jeff D Allen
Samantha A Roberts
P304
P356
10.1377/HLTHAFF.2011.0231
P407
P577
2011-06-16T00:00:00Z